Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Oct 1;29(10):2028-2030.
doi: 10.1093/annonc/mdy339.

TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer

D B Costa  1
Affiliations
Editorial

TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer

D B Costa. Ann Oncol. .
No abstract available

PubMed Disclaimer

Comment on

  • Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
    Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, Ihle MA, Michels S, Nogova L, Fassunke J, Heydt C, Kron F, Ueckeroth F, Serke M, Krüger S, Grohe C, Koschel D, Benedikter J, Kaminsky B, Schaaf B, Braess J, Sebastian M, Kambartel KO, Thomas R, Zander T, Schultheis AM, Büttner R, Wolf J. Kron A, et al. Ann Oncol. 2018 Oct 1;29(10):2068-2075. doi: 10.1093/annonc/mdy333. Ann Oncol. 2018. PMID: 30165392 Free PMC article.

References

    1. Soda M, Choi YL, Enomoto M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448(7153): 561–566. - PubMed
    1. Kwak EL, Bang YJ, Camidge DR. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363(18): 1693–1703. - PMC - PubMed
    1. Camidge DR, Bang YJ, Kwak EL. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13(10): 1011–1019. - PMC - PubMed
    1. Shaw AT, Yeap BY, Mino-Kenudson M. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27(26): 4247–4253. - PMC - PubMed
    1. Shaw AT, Yeap BY, Solomon BJ. et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12(11): 1004–1012. - PMC - PubMed

Substances